KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to 18.26%.

  • Fulgent Genetics' EBITDA Margin rose 55500.0% to 18.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.5%, marking a year-over-year increase of 527100.0%. This contributed to the annual value of 26.08% for FY2024, which is 415300.0% up from last year.
  • According to the latest figures from Q3 2025, Fulgent Genetics' EBITDA Margin is 18.26%, which was up 55500.0% from 24.1% recorded in Q2 2025.
  • Fulgent Genetics' 5-year EBITDA Margin high stood at 74.26% for Q1 2021, and its period low was 214.34% during Q4 2023.
  • Its 5-year average for EBITDA Margin is 8.81%, with a median of 21.17% in 2024.
  • Per our database at Business Quant, Fulgent Genetics' EBITDA Margin crashed by -1603500bps in 2023 and then surged by 1931700bps in 2024.
  • Over the past 5 years, Fulgent Genetics' EBITDA Margin (Quarter) stood at 59.94% in 2021, then plummeted by -190bps to 53.99% in 2022, then crashed by -297bps to 214.34% in 2023, then soared by 90bps to 21.17% in 2024, then grew by 14bps to 18.26% in 2025.
  • Its EBITDA Margin was 18.26% in Q3 2025, compared to 24.1% in Q2 2025 and 26.95% in Q1 2025.